CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net sales	$ 14,227	$ 16,759	$ 44,604	$ 50,572
Cost of goods sold	(13,182)	(15,871)	(41,013)	(47,708)
Gross profit	1,045	888	3,591	2,864
Selling, general and administrative expenses	(447)	(337)	(1,220)	(979)
Interest income	38	30	121	50
Interest expense	(133)	(103)	(374)	(306)
Foreign exchange (losses) gains	(47)	(52)	(64)	(150)
Other income (expense) – net	8	40	35	(13)
Income (loss) from affiliates	39	30	83	95
Income (loss) before income tax	503	496	2,172	1,561
Income tax (expense) benefit	(114)	(113)	(495)	(257)
Net income (loss)	389	383	1,677	1,304
Net (income) loss attributable to noncontrolling interests and redeemable noncontrolling interests	(16)	(3)	(50)	(30)
Net income (loss) attributable to Bunge	$ 373	$ 380	$ 1,627	$ 1,274
Earnings per common share—basic (Note 18)
Net income (loss) attributable to Bunge common shareholders—basic (in dollars per share)	$ 2.50	$ 2.52	$ 10.85	$ 8.59
Earnings per common share—diluted (Note 18)
Net income (loss) attributable to Bunge common shareholders—diluted (in dollars per share)	$ 2.47	$ 2.49	$ 10.71	$ 8.30

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
OPERATING ACTIVITIES
Net income (loss)	$ 1,677	$ 1,304
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities:
Impairment charges	56	86
Foreign exchange (gain) loss on net debt	(151)	(96)
Bad debt expense	8	23
Depreciation, depletion and amortization	317	305
Share-based compensation expense	51	47
Deferred income tax expense (benefit)	115	(92)
Results from affiliates	(100)	(95)
Other, net	57	80
Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:
Trade accounts receivable	306	(359)
Inventories	933	(229)
Secured advances to suppliers	(228)	26
Trade accounts payable and accrued liabilities	(690)	259
Advances on sales	(227)	(81)
Net unrealized (gains) losses on derivative contracts	(247)	(456)
Margin deposits	(111)	(55)
Recoverable and income taxes, net	(19)	(201)
Marketable securities	(17)	341
Beneficial interest in securitized trade receivables	0	(5,288)
Other, net	130	(550)
Cash provided by (used for) operating activities	1,860	(5,031)
INVESTING ACTIVITIES
Payments made for capital expenditures	(805)	(353)
Proceeds from investments	21	217
Payments for investments	(26)	(225)
Settlements of net investment hedges	(57)	(153)
Proceeds from beneficial interest in securitized trade receivables	85	5,176
Proceeds from disposals of businesses and property, plant and equipment	165	496
Payments for investments in affiliates	(136)	(55)
Other, net	107	10
Cash provided by (used for) investing activities	(646)	5,113
FINANCING ACTIVITIES
Net change in short-term debt with maturities of three months or less	161	842
Proceeds from short-term debt with maturities greater than three months	848	1,592
Repayments of short-term debt with maturities greater than three months	(593)	(1,600)
Proceeds from long-term debt	975	48
Repayments of long-term debt	(879)	(1,029)
Proceeds from the exercise of options for common shares	7	30
Repurchases of common shares	(466)	(200)
Dividends paid to common and preference shareholders	(287)	(256)
Capital contributions from (Return of capital to) noncontrolling interest	40	0
Sale of noncontrolling interest	0	521
Acquisition of redeemable noncontrolling interest and noncontrolling interest	0	(102)
Other, net	(19)	52
Cash provided by (used for) financing activities	(213)	(102)
Effect of exchange rate changes on cash and cash equivalents, restricted cash, and cash held for sale	40	112
Net increase (decrease) in cash and cash equivalents, restricted cash, and cash held for sale	1,041	92
Cash and cash equivalents, restricted cash, and cash held for sale - beginning of period	1,152	905
Cash and cash equivalents, restricted cash, and cash held for sale - end of period	$ 2,193	$ 997

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,173	$ 1,104
Trade accounts receivable (less allowances of $101 and $90) (Note 4)	2,509	2,829
Inventories (Note 5)	7,548	8,408
Assets held for sale (Note 2)	1	36
Other current assets (Note 6)	4,393	4,381
Total current assets	16,624	16,758
Property, plant and equipment, net	4,283	3,617
Operating lease assets	864	1,024
Goodwill	472	470
Other intangible assets, net	417	360
Investments in affiliates	1,201	1,012
Deferred income taxes	632	712
Other non-current assets (Note 7)	640	627
Total assets	25,133	24,580
Current liabilities:
Short-term debt (Note 13)	914	546
Current portion of long-term debt (Note 13)	301	846
Trade accounts payable (includes $926 and $643 carried at fair value) (Note 11)	3,975	4,386
Current operating lease obligations	317	425
Liabilities held for sale (Note 2)	0	18
Other current liabilities (Note 10)	2,738	3,379
Total current liabilities	8,245	9,600
Long-term debt (Note 13)	3,967	3,259
Deferred income taxes	380	365
Non-current operating lease obligations	495	547
Other non-current liabilities (Note 16)	900	849
Redeemable noncontrolling interest	3	4
Equity (Note 17):
Common shares, par value $.01; authorized – 400,000,000 shares; issued and outstanding: 2023 – 146,368,303 shares, 2022 – 149,907,932 shares	1	1
Additional paid-in capital	6,727	6,692
Retained earnings	11,555	10,222
Accumulated other comprehensive income (loss) (Note 17)	(6,224)	(6,371)
Treasury shares, at cost; 2023 - 23,163,348 shares and 2022 - 18,835,812 shares	(1,808)	(1,320)
Total Bunge shareholders’ equity	10,251	9,224
Noncontrolling interests	892	732
Total equity	11,143	9,956
Total liabilities, redeemable noncontrolling interest and equity	$ 25,133	$ 24,580